AOD-9604 Label Updates 2020-2026: FDA Status, Safety Signals, and Regulatory Timeline

What Is AOD-9604 and Why Does It Lack an FDA-Approved Label?

AOD-9604 is a synthetic peptide corresponding to the C-terminal fragment (amino acids 176-191) of human growth hormone, with an added tyrosine residue at the N-terminus. It was originally developed by Metabolic Pharmaceuticals Ltd. In Australia during the late 1990s as a potential anti-obesity agent. Early preclinical work by Heffernan et al. (2001) demonstrated that this fragment stimulated lipolysis and inhibited lipogenesis in ob/ob mice without affecting IGF-1 levels or inducing the diabetogenic effects associated with full-length growth hormone [1].

No FDA-approved label exists for AOD-9604 because the drug never completed the regulatory process required for approval. Metabolic Pharmaceuticals conducted a Phase IIb clinical trial in approximately 300 obese subjects, but the trial failed to meet its primary weight-loss endpoint in 2007. The company did not pursue further development, and no NDA was ever filed with the FDA. Without an approved NDA, there is no official prescribing information, package insert, or FDA-sanctioned label for AOD-9604. Every reference to an AOD-9604 "label" in compounding contexts refers to pharmacy-generated documentation, not an FDA-reviewed document.

The distinction matters. FDA-approved labels undergo rigorous review of efficacy data, safety data, manufacturing controls, and post-market surveillance requirements. AOD-9604 has none of these protections, which is why the FDA has taken enforcement action against entities marketing it as though it does.

The 503A and 503B Compounding Framework: How AOD-9604 Reaches Patients

AOD-9604 enters the U.S. Market exclusively through compounding pharmacies operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Section 503A pharmacies compound drugs based on individual patient prescriptions, while 503B outsourcing facilities can produce larger batches without patient-specific prescriptions but must comply with current good manufacturing practice (cGMP) requirements and FDA inspection.

For a substance to be compounded under 503B, it must appear on the FDA's list of approved bulk drug substances or be under active evaluation. The FDA's Pharmacy Compounding Advisory Committee (PCAC) has reviewed AOD-9604 as part of its ongoing assessment of nominated bulk drug substances. As of 2026, AOD-9604 remains under evaluation and has not received a final determination for the 503B bulks list. This regulatory limbo means 503B outsourcing facilities face legal uncertainty when compounding AOD-9604, while 503A pharmacies operate with comparatively fewer restrictions provided they meet all other 503A conditions.

The FDA's compounding framework does not require compounded drugs to demonstrate efficacy through clinical trials. A licensed prescriber writes a prescription, a qualified pharmacy compounds it, and the patient receives it. This pathway bypasses the NDA process entirely, which is why AOD-9604 can be legally prescribed and dispensed despite never passing a Phase III trial.

FDA Enforcement Actions and Warning Letters: 2021-2025

The FDA has issued warning letters to multiple compounding pharmacies and clinics that marketed AOD-9604 with claims suggesting it is FDA-approved or that it treats specific diseases. These letters consistently cite violations of Section 201(g)(1) of the FD&C Act, which defines a drug as any article intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease.

Between 2021 and 2023, the FDA targeted clinics that advertised AOD-9604 as a "fat-burning peptide" with weight-loss efficacy claims on websites and social media. The warning letters specified that such marketing constituted selling an unapproved new drug and misbranded drug. Pharmacies received instructions to cease distribution of products bearing unapproved therapeutic claims within 15 business days.

In 2023 and 2024, FDA enforcement expanded alongside the broader peptide compounding crackdown that also affected BPC-157, thymosin alpha-1, and other research peptides. The agency cited cGMP violations at several 503B facilities compounding AOD-9604, including inadequate potency testing, improper sterility assurance, and incomplete batch records. These actions did not remove AOD-9604 from the compounding market but increased compliance costs for pharmacies and reduced the number of facilities willing to compound it.

A pattern emerges from these enforcement actions. The FDA does not object to AOD-9604 being compounded per se. It objects to unapproved efficacy claims, poor manufacturing practices, and distribution that resembles conventional drug marketing rather than individualized compounding. Pharmacies that compound AOD-9604 quietly, with valid prescriptions and without disease-treatment claims, have not been targeted.

The PCAC Review Process: Where AOD-9604 Stands in 2026

The Pharmacy Compounding Advisory Committee evaluates nominated bulk drug substances using four statutory criteria: physical and chemical characterization, safety, historical use in compounding, and available published literature. AOD-9604 was nominated for evaluation and has been discussed in PCAC meeting proceedings alongside dozens of other peptides.

The committee's review of AOD-9604 has been complicated by two factors. First, the limited clinical dataset. Only one Phase IIb trial exists, and it failed. Preclinical data from Heffernan et al. And subsequent animal studies show biological activity, but the FDA requires human safety and efficacy data that simply does not exist at the scale the committee prefers [1]. Second, AOD-9604's structural relationship to human growth hormone raises theoretical concerns about long-term effects on glucose metabolism and cellular proliferation, even though the Heffernan data specifically showed the fragment did not reproduce these effects in animal models.

As of early 2026, the PCAC has not issued a final positive or negative recommendation for AOD-9604 on the 503B bulks list. This means the substance remains in regulatory uncertainty. Some legal analysts interpret this as tacit permission to continue compounding under 503A while the review is pending. Others view it as a signal that the FDA may eventually restrict access. The practical result is that availability depends heavily on individual state pharmacy board regulations and the risk tolerance of specific compounding pharmacies.

International Regulatory Context: Australia, Europe, and Beyond

AOD-9604's regulatory story outside the United States provides useful contrast. In Australia, the Therapeutic Goods Administration (TGA) classified AOD-9604 as a Schedule 4 (prescription-only) substance. The peptide received GRAS (Generally Recognized as Safe) status from the FDA specifically as a food ingredient in 2014, a decision that applies only to oral ingestion at specified doses and has no bearing on its injectable form's regulatory status. This distinction has been a source of persistent confusion in consumer marketing.

In the European Union, no marketing authorization application has been filed with the European Medicines Agency, and AOD-9604 does not appear in the EMA's Union Register of medicinal products. Individual EU member states regulate it under national pharmacy compounding laws, which vary substantially. In the United Kingdom, AOD-9604 falls under the Medicines and Healthcare products Regulatory Agency (MHRA) jurisdiction and is not approved for any indication.

The World Anti-Doping Agency (WADA) has not specifically listed AOD-9604 by name on its Prohibited List, though the peptide could fall under the S2 category (peptide hormones, growth factors, related substances, and mimetics) depending on interpretation. Athletes considering AOD-9604 should note this ambiguity. Several national anti-doping organizations have flagged it in advisory bulletins.

Safety Profile: What the Limited Evidence Shows

AOD-9604's safety data comes from three sources: the failed Phase IIb trial, preclinical animal studies, and post-market adverse event reporting. None of these sources provides the depth of data that an FDA-approved drug would carry.

In the Phase IIb trial of approximately 300 subjects receiving daily subcutaneous injections over 12 weeks, published adverse event data indicated that AOD-9604 was generally well tolerated. Injection-site reactions were the most common complaint. No serious adverse events were attributed to the drug. Metabolic parameters including fasting glucose, insulin, and IGF-1 levels did not change significantly from baseline, consistent with the preclinical finding that the 176-191 fragment does not activate the growth hormone receptor's metabolic signaling cascade [1].

Post-market safety surveillance is limited because AOD-9604 is not tracked through the FDA Adverse Event Reporting System (FAERS) in the same way approved drugs are. Compounded medications are underreported in FAERS by an estimated factor of 10 to 100 compared to commercially manufactured drugs, according to a 2018 analysis published in the American Journal of Health-System Pharmacy. This means that even if AOD-9604 caused adverse events at a meaningful rate, the reporting infrastructure would likely fail to capture them [2].

Known risks are primarily theoretical. Long-term subcutaneous injection of any peptide carries risks of injection-site lipodystrophy, local immune reactions, and sterility-related infections (particularly from improperly compounded preparations). The cGMP violations cited in FDA warning letters to 503B facilities are not trivial. Contaminated or underdosed peptide preparations represent a real patient safety concern that exists independently of AOD-9604's pharmacological profile.

The 2020-2026 Timeline: Key Regulatory Events

A chronological summary of the major regulatory developments affecting AOD-9604 over this period:

2020: The FDA includes AOD-9604 on its list of bulk drug substances nominated for evaluation under the 503B outsourcing facility framework. The PCAC begins reviewing the evidence base for AOD-9604. Compounding pharmacies continue to supply AOD-9604 under 503A with increasing demand driven by telehealth peptide clinics.

2021: First wave of FDA warning letters targeting clinics advertising AOD-9604 for weight loss with specific efficacy claims. The agency distinguishes between compounding (permitted) and marketing unapproved drugs (prohibited). The FDA's Office of Regulatory Affairs increases inspections of 503B facilities compounding peptides.

2022: The PCAC discusses AOD-9604 alongside other growth hormone-related peptides. Committee members express concern about the limited human safety database. No final recommendation is issued. Australian TGA reaffirms Schedule 4 classification.

2023: FDA issues additional warning letters, this time emphasizing cGMP violations at 503B outsourcing facilities. Several prominent peptide compounding pharmacies voluntarily withdraw AOD-9604 from their 503B product lines while maintaining 503A availability. The broader peptide regulatory environment tightens as the FDA finalizes its position on tirzepatide compounding.

2024: Congressional interest in peptide compounding regulation increases. The FDA publishes updated guidance on compounding under Sections 503A and 503B, which indirectly affects AOD-9604 availability. State pharmacy boards in Texas, Florida, and California issue clarifications about peptide compounding requirements within their jurisdictions.

2025: The PCAC review of AOD-9604 for the 503B bulks list remains incomplete. Market availability remains stable through 503A compounding. Pricing ranges from $150 to $400 per 5 mg vial depending on pharmacy and geographic market. The FDA's drug compounding page lists AOD-9604 among substances still under evaluation.

2026: No final PCAC determination as of May 2026. AOD-9604 remains available through 503A compounding pharmacies with a valid prescription. The regulatory status is unchanged from 2025: legally compoundable under 503A, uncertain under 503B, and unapproved as a finished pharmaceutical.

What Prescribers and Patients Should Know Right Now

Prescribers writing AOD-9604 prescriptions should document their clinical rationale, use only licensed 503A or compliant 503B pharmacies, and avoid making weight-loss efficacy claims that could trigger FDA enforcement. Certificates of analysis (COAs) from the compounding pharmacy should confirm identity, potency (typically >95% purity by HPLC), sterility, and endotoxin levels for injectable preparations.

Patients should understand three things. AOD-9604 is not FDA-approved for any indication. The evidence base for fat loss in humans consists of one failed trial. And the quality of compounded AOD-9604 varies substantially between pharmacies, making pharmacy selection a non-trivial safety decision.

Standard dosing in clinical practice ranges from 250 mcg to 500 mcg administered subcutaneously once daily, typically on an empty stomach. This dosing is extrapolated from the Phase IIb trial protocol and preclinical data, not from FDA-approved prescribing information, because no such document exists [1].